Aclaris Therapeutics Inc [ACRS] stock prices are up 0.43% to $2.31 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ACRS shares have gain 5.00% over the last week, with a monthly amount drifted -10.12%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Aclaris Therapeutics Inc [NASDAQ: ACRS] stock has seen the most recent analyst activity on December 23, 2024, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $20 for it. Previously, Cantor Fitzgerald upgraded its rating to Overweight on November 20, 2024. On November 19, 2024, upgrade upgraded it’s rating to Outperform and revised its price target to $7 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $7 on November 19, 2024. BTIG Research upgraded its rating to a Buy but $8 remained the price target by the analyst firm on November 19, 2024. Piper Sandler upgraded its rating to Overweight for this stock on November 18, 2024, and upped its price target to $13. In a note dated January 22, 2024, H.C. Wainwright downgraded an Neutral rating on this stock.
The stock price of Aclaris Therapeutics Inc [ACRS] has been fluctuating between $0.95 and $5.17 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Aclaris Therapeutics Inc [NASDAQ: ACRS] shares were valued at $2.31 at the most recent close of the market. An investor can expect a potential return of 159.74% based on the average ACRS price forecast.
Analyzing the ACRS fundamentals
The Aclaris Therapeutics Inc [NASDAQ:ACRS] reported sales of 27.08M for trailing twelve months, representing a drop of -53.18%. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -1.5%, Pretax Profit Margin comes in at -1.38%, and Net Profit Margin reading is -1.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.26 and Total Capital is -0.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.24 points at the first support level, and at 2.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.40, and for the 2nd resistance point, it is at 2.48.
Ratios To Look Out For
It’s worth pointing out that Aclaris Therapeutics Inc [NASDAQ:ACRS]’s Current Ratio is 7.03. Also, the Quick Ratio is 7.03, while the Cash Ratio stands at 2.53. Considering the valuation of this stock, the price to sales ratio is 9.13, the price to book ratio is 1.27.
Transactions by insiders
Recent insider trading involved Mehra Anand, Director, that happened on Nov 19 ’24 when 0.67 million shares were purchased. 10% Owner, Leonard Braden Michael completed a deal on Aug 05 ’24 to buy 0.21 million shares. Meanwhile, 10% Owner Leonard Braden Michael bought 0.17 million shares on Aug 02 ’24.
